INmune Bio's Alzheimer's drug misses mid-stage goal, shares sink to record low
  INmune Bio's Alzheimer's drug falls short of mid-stage study goal, shares tumble
  Vor Bio back from brink with autoimmune drug deal rising to $4bn
  Instil Bio Shares Climb After FDA Clears Tumor Treatment Application
  INmune Bio slumps on midstage fail for Alzheimer's drug
  A revolutionary drug made in N.J. is giving cancer patients years of their lives back
  Sunshine Biopharma’s Canadian subsidiary, Nora Pharma launches biosimilar drug, Niopeg
  Vor Bio's surprise $4B revival deal for RemeGen's autoimmune drug triggers divergent stock reactions